Literature DB >> 2401455

Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis.

A Stiehl1, G Rudolph, R Raedsch, B Möller, U Hopf, E Lotterer, J Bircher, U Fölsch, J Klaus, R Endele.   

Abstract

Ursodeoxycholic acid treatment of patients with primary biliary cirrhosis may lead to relief of pruritus and improvement of biochemical liver tests. The changes in serum and urinary bile acids induced by ursodeoxycholic acid treatment were studied. After 29 patients with primary biliary cirrhosis were treated with ursodeoxycholic acid (750 to 1,000 mg/day) for 6 to 12 mo because of an increase in ursodeoxycholic acid, total plasma bile acids increased from 30.5 +/- 6 mumol/L (mean +/- S.E.M.) to 52.7 +/- 11.7 mumol/L (p less than 0.01). The increase in total plasma bile acids correlated significantly with concentrations of plasma bile acid before treatment (p less than 0.01). The concentrations of endogenous bile acids decreased, mainly because of a decrease of cholic acid. During treatment, glycine conjugation increased and taurine conjugation decreased, whereas sulfation and glucuronidation of bile acids were unchanged. In 10 patients with primary biliary cirrhosis in stages III and IV, urinary excretion of bile acids was also studied. After treatment, ursodeoxycholic acid and its 3-beta isomer and C-1-hydroxylated and C-6-hydroxylated derivatives were also excreted. During treatment, urinary excretion of endogenous bile acids decreased. The increase of ursodeoxycholic acid and the decrease of endogenous bile acids may both be related to the improvement of biochemical liver tests in precirrhotic stages of the disease. In cirrhosis, endogenous bile acids in plasma remained high and changes in liver tests were small.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2401455     DOI: 10.1002/hep.1840120308

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  27 in total

Review 1.  Recent developments in primary biliary cirrhosis: etiology and treatment.

Authors:  U Hopf; R Stemerowicz
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

2.  The ursodeoxycholic acid story in primary biliary cirrhosis.

Authors:  A G Lim; R P Jazrawi; T C Northfield
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

3.  Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C.

Authors:  M Mohler; S Seipp; U Tox; W Stremmel; L Theilmann; T Goeser
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

Review 4.  Ursodeoxycholic acid in the treatment of liver diseases.

Authors:  S Saksena; R K Tandon
Journal:  Postgrad Med J       Date:  1997-02       Impact factor: 2.401

5.  Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells.

Authors:  Wei Fan; Heping Yang; Ting Liu; Jiaohong Wang; Tony W H Li; Nirmala Mavila; Yuanyuan Tang; JinWon Yang; Hui Peng; Jian Tu; Alagappan Annamalai; Mazen Noureddin; Anuradha Krishnan; Gregory J Gores; Maria L Martínez-Chantar; José M Mato; Shelly C Lu
Journal:  Hepatology       Date:  2017-01-31       Impact factor: 17.425

6.  Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis.

Authors:  K E Kisand; A L Karvonen; M Vuoristo; M Färkkilä; J Lehtola; J Inkovaara; K V Kisand; T Miettinen; K Krohn; R Uibo
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

7.  Influence of cholestasis on absorption of ursodeoxycholic acid.

Authors:  P Sauer; C Benz; G Rudolph; P Klöters-Plachky; W Stremmel; A Stiehl
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

8.  Characterisation of patients with a complete biochemical response to ursodeoxycholic acid.

Authors:  R A Jorgensen; E R Dickson; A F Hofmann; S S Rossi; K D Lindor
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

9.  Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.

Authors:  S Güldütuna; M Leuschner; N Wunderlich; A Nickel; S Bhatti; K Hübner; U Leuschner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Bile acids in treatment of ocular disease.

Authors:  Jeffrey H Boatright; John M Nickerson; Anisha G Moring; Machelle T Pardue
Journal:  J Ocul Biol Dis Infor       Date:  2009-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.